Thomas Vranken

Thomas Vranken requested quantification of market share gains for the GPS test and asked about the company's key milestones beyond achieving adjusted EBITDA profitability.

Answer

CEO Michael McGarrity declined to quantify specific market share figures but stated that the company's high growth rates demonstrate they are both converting the market away from non-use of biomarkers and taking share from competitors. Looking forward, he said key milestones will be continued execution on top-line growth and OpEx discipline, allowing the business to fund itself and solidifying MDxHealth's position as the leading growth company in urology diagnostics.

Thomas Vranken of KBC Securities questioned the company's current thinking on the breadth of its test menu, including potential new additions in 2025, and asked about the impact of Medicare reimbursement on commercial payer coverage for the Select mdx test.

Answer

CEO Michael McGarrity stated that the current test menu is sufficient to meet growth objectives for the foreseeable future and that 2025 guidance does not assume any new test additions. He added that across the menu, unit growth is strong, pricing is stable or accelerating, and the managed care team continues to successfully expand coverage with commercial payers.

Thomas Vranken requested an update on the integration of the new germline test, including the timeline for its revenue contribution, and asked about the company's current outlook on pursuing additional opportunities to expand its testing menu.

Answer

Executive Michael McGarrity stated that the germline test is in a limited launch in Q3 to validate the business case and gather payment history, with revenue contribution expected in the second half of the year. On menu expansion, he confirmed MDxHealth actively evaluates a 'dashboard of opportunities' and noted that the company's strong commercial channel now attracts inbound interest, a process supported by the strategic expertise of new board member Sandy Segal.